Scientists from the Research Center Borstel, the German Center for Infection Research, the Oxford Biomedical Research Centre and the South African National Institute for Communicable Diseases have developed a new genetic method, with which they can not only predict which antibiotics result in resistance, but with which they can also say which compounds are effective against the respective tuberculosis (TB) pathogens. The results will be published on Wednesday, June 24 in the online edition of the international journal The Lancet Infectious Diseases.
Detection of TB pathogens and the precise determination of antibiotic resistance was, until now, only done with culture procedures. This method requires up to six weeks until a result is available. Valuable time, which frequently delays effective treatment.
The procedures using cultures are also relatively prone to error. They need to be very precise, however, in order to obtain reliable and comparable results, and such ideal lab conditions are also usually not available in countries with high tuberculosis rates, in particular. Even the molecular-diagnostic quick tests used over the last 20 years can only provide information on a limited number of mutations and the resistances which result from them.
"We wanted to go one step further and give therapeutic pointers on which combinations of antibiotics are suitable for treating a certain pathogen", summarized Professor Stefan Niemann, Head of the Molecular Mycobacteriology research group at the Research Center Borstel and member of the Cluster of Excellence Inflammation at Interfaces, to describe the research approach. "We are moving from 130 years of TB cultivation towards a new, digital era in microbiology."
To do so, the team investigated the genomes from around 3500 strains of TB, using the Whole Genome Sequencing method (WGS). The researchers concentrated on changes to the genome which they could connect to antibiotic resistance and sensitivity.
"We have established a kind of dictionary for mutations in the genomes of TB pathogens", explained Niemann. "If changes to the genetic code are found in a patient isolate, then certain medications are no longer effective and should therefore not be used for treatment. This is an enormous advance in progress, particularly in terms of treating multi-resistant pathogens!"
It will take some time until the method can be applied by physicians in everyday practise. However Dr Thomas Kohl, co-author of the publication, believes that the method has great potential: "In the long term, genome analysis is significantly easier and cheaper to carry out than developing cultures. Above all, with regard to the WHO EndTB strategy, which plans to successfully end tuberculosis by 2035, these new diagnostic approaches are very important."
Tuberculosis (TB) is the most frequent deadly contagious disease worldwide. Estimates think that around one third of the world's population is infected with the pathogen. For the majority of those infected, however, tuberculosis never breaks out. Each year 9 million people contract TB - and around 1.5 million die as a result of its consequences. The ever increasing antibiotic resistances of the pathogens are an immense problem. This considerably extends the duration of treatment and causes high costs.
Walker, TM, Kohl, TA, Omar, SV, Hedge, J, Elias, CDO, Bradley, P, Iqbal, Z, Feuerriegel, S, Niehaus, KE, Wilson, DJ, Clifton, DA, Kapatai, G, Ip, C, Bowden, R, Drobniewski, FA, Allix-Béguec, C, Gaudin, C, Parkhill, J, Diel, R, Supply, P, Crook, DW, Smith, EG, Walker, AS, Ismail, N, Niemann, S, Peto, TEA and Modernizing Medical Microbiology (MMM) Informatics Group (2015): Whole-genome sequencing for prediction of Mycobacterium
tuberculosis drug susceptibility and resistance: a retrospective cohort study. The Lancet Infectious Diseases, http://dx.doi.org/10.1016/S1473-3099(15)00062-6 (as from June 24, 01:00 CET)
Professor Dr Stefan Niemann
Research Center Borstel / Cluster of Excellence Inflammation at Interface s
German Center for Infection Research
Tel.: +49 (0)4537/ 188-7620
Dr Tebke Böschen
Tel: +49 (0)431 880-4682, e-mail: firstname.lastname@example.org
Tel: +49 (0)4537 188-2890, e-mail: email@example.com
Dr. Tebke Böschen | idw - Informationsdienst Wissenschaft
Researchers identify how bacterium survives in oxygen-poor environments
22.11.2017 | Columbia University
Researchers discover specific tumor environment that triggers cells to metastasize
22.11.2017 | University of California - San Diego
15.11.2017 | Event News
15.11.2017 | Event News
30.10.2017 | Event News
22.11.2017 | Medical Engineering
22.11.2017 | Materials Sciences
22.11.2017 | Health and Medicine